聚焦超声波thalamotomy针对帕金森病的概率性精细化
Cletus Cheyuo1,2, Jürgen Germann2, Kazuaki Yamamoto2,3,4
1Department of Neurosurgery, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA.
概括
精细化磁共振图像引导聚焦超声波 (MRgFUS) 乳头切除的目标改善了基本震 (ET) 和震主导的帕金森病 (TDPD) 的结果. 该研究确定了每个条件的不同的最佳目标,提高了对震控制的有效性.
科学领域:
- 神经外科 神经外科
- 神经学 神经学
- 医疗成像医学成像
背景情况:
- 针对MR指导聚焦超声波 (MRgFUS) 胸膜切除术的临床结果在基本震 (ET) 和震主导的帕金森病 (TDPD) 之间存在显著差异.
- 一个标准化的MRgFUS乳头切除的目标并不能为ET和TDPD提供最佳的结果.
研究的目的:
- 与ET相比,改进MRgFUS thalamotomy对TDPD的目标与ET相比.
- 为了确定疾病特定的目标,以改善震控制.
主要方法:
- 在32名TDPD和79名ET患者中,对voxel-wise疗效和结构连接性映射的回顾性分析.
- 利用手术后的手震得分和T1加权的大脑图像.
- 在9名TDPD患者的独立队列中验证的结果使用统一帕金森病评级尺度第三部分.
主要成果:
- MRgFUS 乳头切除术在TDPD和ET之间的疗效图表中显示出显著的差异 (p<0.05).
- 最佳的TDPD目标位于ET目标前方约3.5毫米,背部约3毫米.
- 一个特定于疾病的疗效图准确地预测了TDPD患者的结果 (R=0.8,R2=0.64).
结论:
- 对于TDPD,最有效的MRgFUS乳头切除术目标是在腹腔中间核/腹腔口腔后边界区域内.
- 这些发现为 thalamic 参与震控制提供了新的见解.
- 优化,特定于疾病的向对改善运动障碍MRgFUS治疗结果具有关键意义.
相关概念视频
01:24Parkinson's Disease: Treatment
241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241
01:15Parkinson's Disease: Overview
508
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
508